Search
Segesterone acetate
go.drugbank.com/drugs/DB14583ApprovedSegesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S.
Synonyms: 16-Methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dioneAmivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCoal tar
go.drugbank.com/drugs/DB11082ApprovedCoal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. … It has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema.
Mixtures: COCOIS CO. OINTMENTCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same
Duloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigational[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amineRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalBy inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. … [A229883] Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation.
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalDue to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.
Escitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalto other SSRIs. … as compared to other agents in this class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: NEO ZENTIUS® 10 MG, NEO ZENTIUS® 20 MG COMPRIMIDOS